Literature DB >> 22870136

Detection of fecal interferon-induced transmembrane protein messenger RNA for colorectal cancer screening.

Chie Miyamoto1, Nobuki Miyamoto, Hiroyuki Yamamoto, Kohzoh Imai, Yasuhisa Shinomura.   

Abstract

Interferon-induced transmembrane protein (IFITM) is reported to be frequently overexpressed in colorectal tumors. This study aimed to determine the usefulness of detecting fecal IFITM messenger RNA (mRNA) by real-time reverse-transcription polymerase chain reaction (RT-PCR) for colorectal cancer (CRC) screening. This pilot study included 21 patients with CRC and 23 healthy controls. Total RNA was isolated from the feces of the patients, and the expression levels of the mRNA of IFITM1, IFITM2 and IFITM3 were measured by real-time RT-PCR to detect CRC. Receiver operating characteristic curves of respective genes were generated, and the area under the curve (AUC), sensitivity and specificity were determined. When the 44 patients were analyzed, the AUCs of fecal IFITM1, IFITM2 and IFITM3 expression analysis were 0.82, 0.80 and 0.65, respectively. The sensitivities were 67% [14/21; 95% confidence interval (CI) 43-85%], 67% (14/21; 95% CI 43-85%) and 71% (15/21; 95% CI 48-89%), respectively; and the specificities were 96% (1/23; 95% CI 78-100%), 96% (1/23; 95% CI 78-100%) and 61% (9/23; 95% CI 39-80%), respectively. When IFITM1 and IFITM2 were combined, the sensitivity was 86% (18/21; 95% CI 64-97%) and the specificity was 96% (1/23; 95% CI 78-100%). The fecal expression analysis of IFITM1 and IFITM2 mRNA by real-time RT-PCR for CRC screening exhibited high specificities, and the sensitivity was further improved by combining IFITM1 and IFITM2.

Entities:  

Year:  2010        PMID: 22870136      PMCID: PMC3412474          DOI: 10.3892/ol.2010.197

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

1.  Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia.

Authors:  O Kitahara; Y Furukawa; T Tanaka; C Kihara; K Ono; R Yanagawa; M E Nita; T Takagi; Y Nakamura; T Tsunoda
Journal:  Cancer Res       Date:  2001-05-01       Impact factor: 12.701

2.  Abnormal expression of CD44 variants in the exfoliated cells in the feces of patients with colorectal cancer.

Authors:  T Yamao; Y Matsumura; Y Shimada; Y Moriya; K Sugihara; T Akasu; S Fujita; T Kakizoe
Journal:  Gastroenterology       Date:  1998-06       Impact factor: 22.682

3.  Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.

Authors:  Wai K Leung; Ka-Fai To; Ellen P S Man; Michael W Y Chan; Aric J Hui; Simon S M Ng; James Y W Lau; Joseph J Y Sung
Journal:  Am J Gastroenterol       Date:  2007-03-22       Impact factor: 10.864

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Detecting colorectal cancer in stool with the use of multiple genetic targets.

Authors:  S M Dong; G Traverso; C Johnson; L Geng; R Favis; K Boynton; K Hibi; S N Goodman; M D'Allessio; P Paty; S R Hamilton; D Sidransky; F Barany; B Levin; A Shuber; K W Kinzler; B Vogelstein; J Jen
Journal:  J Natl Cancer Inst       Date:  2001-06-06       Impact factor: 13.506

6.  Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer.

Authors:  Konstanze Lenhard; Guido T Bommer; Silke Asutay; Rolf Schauer; Thomas Brabletz; Burkhard Göke; Rolf Lamerz; Frank T Kolligs
Journal:  Clin Gastroenterol Hepatol       Date:  2005-02       Impact factor: 11.382

7.  A quantitative immunochemical fecal occult blood test for colorectal neoplasia.

Authors:  Zohar Levi; Paul Rozen; Rachel Hazazi; Alex Vilkin; Amal Waked; Eran Maoz; Shlomo Birkenfeld; Moshe Leshno; Yaron Niv
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

8.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

9.  Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis.

Authors:  Yoshikatsu Koga; Masahiro Yasunaga; Yoshihiro Moriya; Takayuki Akasu; Shin Fujita; Seiichiro Yamamoto; Takahiro Kozu; Hideo Baba; Yasuhiro Matsumura
Journal:  Cancer Sci       Date:  2008-10       Impact factor: 6.716

10.  Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening.

Authors:  Shigeru Kanaoka; Ken-Ichi Yoshida; Naoyuki Miura; Haruhiko Sugimura; Masayoshi Kajimura
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

View more
  3 in total

1.  A transcriptomic signature that predicts cancer recurrence after hepatectomy in patients with colorectal liver metastases.

Authors:  Yuma Wada; Mitsuo Shimada; Yuji Morine; Tetsuya Ikemoto; Yu Saito; Hideo Baba; Masaki Mori; Ajay Goel
Journal:  Eur J Cancer       Date:  2022-01-14       Impact factor: 9.162

Review 2.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

Review 3.  Malignancy and IFITM3: Friend or Foe?

Authors:  Ushani S Rajapaksa; Chen Jin; Tao Dong
Journal:  Front Oncol       Date:  2020-12-08       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.